Overview

A Clinical Study of B001 Injection in the Treatment of Neuromyelitis Optica Spectrum Disorders(NMOSD)

Status:
RECRUITING
Trial end date:
2029-02-28
Target enrollment:
Participant gender:
Summary
To evaluate the efficacy and safety of B001 injection in aquaporin-4 antibody positive patients with neuromyelitis optica spectrum disorder.
Phase:
PHASE2
Details
Lead Sponsor:
Shanghai Jiaolian Drug Research and Development Co., Ltd
Collaborator:
Shanghai Pharmaceuticals Holding Co., Ltd